Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

Safe Pro Group's AI technology for drone-based imagery processing continues to confirm its remarkable sensing capabilities for the detection of landmines and UXO (unexploded ordnance).

The company's AI is trained on data collected by a wide range of end users, providing Safe Pro Group with diverse dataset drawn from a wide range of missions, including commercial, military, and humanitarian roles.

Safe Pro Group has entered into numerous partnerships with leaders in the drone industry as the company's technology proves its reliability.

Safe Pro Group (NAS D AQ: SPAI) , a technology company that offers AI-powered defense and security solutions, recently announced that the company's AI models have analyzed and processed over 2 million images and detected over 36,000 real-world landmines and UXO ( https://ibn.fm/EsujE ).

Safe Pro Group (NASDAQ: SPAI) successfully demonstrated its AI-powered drone imagery analysis system during a recent training event with the Philippine Army at Camp Aquino in Tarlac. The demonstration showcased SPAI's patented Safe Pro Object Threat Detection ("SPOTD") technology, which can identify over 150 types of hard-to-detect threats such as landmines, unexploded ordnance ("UXO"), and cluster munitions. Over 30 Explosive Ordnance Disposal ("EOD") technicians were taught how drone imagery analysis can improve the detection of these dangerous threats. SPAI's patented technology has unique real-world datasets—analyzing nearly 2 million drone images and detecting over 34,000 threats in Ukraine. The initiative highlights SPAI's growing role in advancing AI-driven demining efforts across the Asia-Pacific region.

To view the full article, visit https://ibn.fm/aYLYo

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Friday's trading session at $8.95, up 18.8579%, on 1,633,128 volume. The average volume for the last 3 months is 397,672 and the stock's 52-week low/high is $1.47/$9.1599.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Expands Asia-Pacific Reach with AI-Based SPOTD Technology
• Safe Pro Group Inc. (NASDAQ: SPAI) Has Processed Over 2 Million Drone Images and Detected More Than 36,000 Landmines and UXO with Its Battle-Tested AI Technology
• Safe Pro Group Inc. (NASDAQ: SPAI) and Red Cat Holdings Collaboration to Bring Cutting-Edge AI Threat Detection Capabilities to Black Widow(TM) Drones

Bollinger Innovations, Inc. (NASDAQ: BINI)

The QualityStocks Daily Newsletter would like to spotlight Bollinger Innovations, Inc. (NASDAQ: BINI).

Electric vehicles used for e-commerce deliveries could dramatically reduce urban emissions as online shopping continues expanding globally, the United Nations Environment Program (UNEP) says. Major delivery platforms recently launched Deliver-E in Dubai to electrify their vehicle fleets, with UNEP coordinating through its Global Electric Mobility Program. Founding members include Delivery Hero, DoorDash, iFood, Mr. D, Swiggy, Uber, Wolt, and Zomato, whose combined operations span numerous countries with billions of annual delivery trips. UNEP's initiative, funded through the European Union's SOLUTIONSplus program, supports Ecuador's plan to designate historic Quito a zero-emissions district while potentially providing a model for other cities addressing motorcycle pollution. Coalition members will focus on evidence gathering, technology assessment, lesson sharing, and practical coordination over immediate fleet conversion requirements. Deliver-E participants will then exchange proven approaches to enabling faster collective advancement through shared learning and coordinated rollouts across varied markets. EV makers like Bollinger Innovations, Inc. (NASDAQ: BINI) that are selling electrified delivery vans have an opportunity to tap into these foreign markets that are adopting electric means of delivering products in urban centers. 

About GreenCarStocks

Bollinger Innovations, Inc. (NASDAQ: BINI) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with United States-based manufacturing located in Tunica, Mississippi.

In August 2023, Mullen began commercial vehicle production in Tunica. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Mullen Automotive. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

Mullen Commercial

Mullen is defining a new era in commercial vehicles with its connected and customized solutions aimed at making businesses more efficient and profitable.

Mullen ONE Class 1 EV Cargo Van

The Mullen ONE class 1 commercial electric vehicle is the first of its kind in the U.S. market. This van was designed to navigate within narrow urban streets and residential roads, all while maximizing payload and cargo space. The Mullen ONE’s height is less than 6.5 feet, meaning your driver can park the vehicle in a residential garage.

Mullen THREE Class 3 Electric Truck

The efficient urban utility low cab forward features a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. Even in reverse, maneuverability is a breeze with our standard backup camera and 7-inch display screen. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,300 lbs of payload. In addition, the design of the LCF chassis allows more cargo length within a given overall length.

Mullen Commercial EVs are eligible for several federal and state level EV incentives, which can be combined for maximized savings.

Mullen ONE:

• $7,500 Federal Tax Credit
• $3,500 MOR-EV Incentive (Massachusetts only)
• $7,500 ComEd Business & Public Sector EV Rebate Program (Illinois only)

Mullen THREE:

• $7,500 Federal Tax Credit
• $45,000 California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) (California only)
• $15,000 MOR-EV Incentive (Massachusetts only)
• $30,000 ComEd Business & Public Sector EV Rebate Program (Illinois only)

In the last two years, Mullen has conducted over 100 vehicle demos or pilots across various industries in the U.S. resulting in significant progress, including new sales opportunities and vehicle orders received and or completed:

• Universities: Princeton University, University of Virginia (UVA), University of California, Los Angeles (UCLA)
• Local city governments: Cities of Dublin, Ohio, Raleigh, North Carolina, Los Angeles, California, Seattle, Washington and Orange County, North Carolina
• Small businesses: From local florist shops to health care providers delivering supplies

Mullen has an extensive dealer network in the U.S. with renowned dealers nationwide including:

• Papé Group (California, Oregon, Washington)
• National Auto Fleet Group (California)
• Pritchard EV (Iowa)
• Eco Auto (Massachusetts)
• Ziegler Truck Group (Minnesota)
• Range Truck Group (Washington)
• Mullen Commercial Vehicle Center (California)

Mullen Commercial EVs are available for purchase on Sourcewell under NAFG’s Sourcewell Contract # 091521-NAF which offers Class 1-3 light duty trucks, cars, vans, SUVs, cab chassis, and electric vehicles with related equipment and accessories to U.S. government agencies.

Bollinger Motors

Mullen entered the medium-duty truck classes through its September 2022 acquisition of a controlling interest in EV truck innovator Bollinger Motors. The acquisition gave Mullen access to a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets, such as last-mile delivery, refrigeration, utilities and upfitters.

The 2025 Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger’s unique chassis design protects the 158-kWh battery pack and components to offer unparalleled capability and safety in the commercial market. The vehicle also features a payload in excess of 7,300 pounds with an average driving range of 185 miles. Bollinger Motors began serial production of the B4 on Sept. 16 via its manufacturing partnership with Roush Industries at their facility in Livonia, Michigan.

Bollinger Motors has passed numerous milestones in recent months, including:

• 30 B4s delivered and paid for, worth nearly $4.5 million, since start of production
• Its production launch on Sept. 16 at Roush Industries in Livonia, Michigan
• Achieving FMVSS compliance
• Receiving the Certificate of Conformity from the Environmental Protection Agency, and CARB certification
• The creation of a world-class dealer and service network
• An agreement with Our Next Energy in Novi, Michigan, for battery packs
• Providing a full warranty coverage of the B4 chassis cab
• Announcing Syncron as its warranty administration partner and Amerit Fleet Solutions as its mobile service provider
• A partnership with EO to power EV charging infrastructure, equipment and technology solutions for Bollinger’s dealers and customers

Bollinger Motors has qualified for multiple federal and state incentive programs, including:

• Inflation Reduction Act incentives of up to $40,000 per vehicle
• California: Innovative Small e-Fleet (ISEF) Pilot Program, with incentives up to $120,000 per vehicle
• Massachusetts: voucher of up to $30,000 per vehicle from Massachusetts Offers Rebates for Electric Vehicles (MOR-EV)
• New York: up to $100,000 from NYTVIP through NYSERDA
• Pennsylvania: up to a $20,000 grant from Alternative Fuels Incentive Grant Program (AFIG) of the Pennsylvania Department of Environmental Protection

Mullen FIVE RS

The Mullen FIVE RS is an ultra-high-performance EV Crossover featuring a top speed of over 200 mph and acceleration from 0-60 mph in under 2 seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, two-speed gearbox, and over 1,100 horsepower.

The Mullen FIVE RS is planned for launch in Germany with vehicle sales planned for December 2025. Initial vehicle market territories include the EU in 2025, followed by the UAE and South Africa in early 2026.

Mullen is partnering with Faissner Petermeier Fahrzeugtechnik AG (“FPF”), which has decades of experience in the development and production of serial components and sophisticated vehicles for global brands such as Piech Automotive, Gumpert Automotive and is in partnership with BMW of all the above. FPF is certified according to the IATF standard and fulfills all the special requirements of the Federal Motor Transport Authority in Germany.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

Mullen is led by an executive team with extensive EV, OEM and high-growth startup experience.

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working towards a sustainable future by creating a suite of clean-energy, electric vehicles at varied price points. With entirely US based manufacturing and operations, Mr. Michery is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Bollinger Innovations, Inc. (NASDAQ: BINI), closed Friday's trading session at $0.1345, up 30.5825%, on 1,525,158 volume. The average volume for the last 3 months is 3,165,520 and the stock's 52-week low/high is $0.1021/$138000000000.

Recent News

• Bollinger Innovations, Inc. (NASDAQ: BINI) - Using EVs for Ecommerce Deliveries Could Slash Urban Emissions, UNEP Says
• WEF Calls for Systems Thinking to Leverage Energy Nexus
• US EV Industry Transforms as Expired Incentives Become New Reality

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF)

The QualityStocks Daily Newsletter would like to spotlight Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF).

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second scan time, high spatial resolution surpassing MRI, and radiation levels comparable to conventional mammography, the system streamlines diagnosis while enhancing patient safety and experience. Built as a scalable platform, IzoView supports future software-driven clinical applications—from screening to treatment monitoring—maximizing ROI for healthcare providers. Its self-shielding design also eliminates the need for facility retrofits, expanding accessibility across diverse imaging environments.

To view the full article, visit https://ibn.fm/uMXHa

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.

Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global market. Its vision centers on redefining how breast imaging is performed—shifting away from adaptations of whole-body scanners or 2D mammography toward a fully dedicated approach optimized for breast anatomy.

The company’s strategy is built around a singular platform with expansion potential. Izotropic is focused on commercializing its lead product through a staged pathway that includes regulatory authorization, clinical validation, and strategic investor engagement. In parallel, the company is developing educational tools and communications platforms to raise awareness among patients, clinicians, and stakeholders about the evolving role of dedicated breast imaging technologies in cancer care.

The company is headquartered in Vancouver, British Columbia, with operations in Sacramento, California.

Technology Portfolio

Izotropic’s flagship product is the IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without compression. The IzoView system was advanced from academic innovation to commercial readiness by Izotropic’s in-house team, building on exclusively licensed technology developed at the University of California, Davis to optimize diagnostic accuracy, patient comfort, and clinical workflow. IzoView integrates proprietary mechanical design, patented hardware innovations, and trade-secret software algorithms, along with AI-driven enhancements designed to improve radiologist performance.

Now in clinical-ready form and housed at Izotropic’s engineering facility in Sacramento, California, IzoView was built under an ISO 13485-compliant quality management system. It is scheduled for use in the company’s planned U.S. clinical trial for FDA market authorization. The device is also central to the company’s broader commercialization strategy, which includes platform extensions and future imaging-based product lines outlined in its recently completed 150-page business plan and financial model.

In preparation for launch, Izotropic is also rolling out strategic awareness platforms. These include a company-hosted podcast and the development of breastct.com, a new educational resource to support patients, clinicians, and stakeholders. These initiatives are designed to enhance engagement, reinforce brand positioning, and build early market traction for IzoView.

Market Opportunity

Izotropic is targeting the global breast imaging market, which is undergoing rapid innovation as healthcare providers seek more accurate, patient-friendly alternatives to traditional mammography. Current screening technologies have well-documented limitations in detecting tumors in women with dense breast tissue, a challenge IzoView directly addresses.

According to a report by MarketsandMarkets, the breast imaging market is projected to grow from $4.3 billion in 2023 to $6.6 billion by 2028, at a compound annual growth rate (CAGR) of 8.9%. Key drivers include the increasing prevalence of breast cancer, the shift toward early detection, and advances in imaging technology such as AI integration and contrast-enhanced diagnostics.

Izotropic’s licensing structure with UC Davis allows the company to pursue either FDA or CE Mark approval, offering flexibility for U.S. and international market entry. Izotropic’s go-to-market plan is supported by ongoing education efforts and a structured clinical strategy, both aligned to accelerate adoption and unlock value in a growing global market.

Leadership Team

Robert Thast, Interim CEO, is the founding executive of Izotropic and has over 30 years of experience leading public companies. He has raised over $100 million in capital, built cross-functional leadership teams, and guided early-stage ventures through public listings and strategic transitions. At Izotropic, he oversees corporate development, financing, and market strategy.

Dr. John Boone, Ph.D., Principal Founder and Director, is a Distinguished Professor of Radiology and Biomedical Engineering at UC Davis. He is a pioneer in breast CT development, having built and tested four dedicated scanners and led trials with nearly 500 women. He has held top roles in AAPM and RSNA and currently serves as Editor-in-Chief of Medical Physics.

Ralph Proceviat, CPA, CFO and Director, brings more than four decades of experience in finance, restructuring, and cross-border operations. He has served as CEO, President, and CFO across multiple sectors and has raised significant capital for both public and private ventures. He is also the founder of C-Suite-Consulting.

Dr. Younes Achkire, Ph.D., Chief Operating Officer and Lead Engineer, is the technical lead behind IzoView. He previously co-founded Zap Surgical Systems and has commercialized FDA-cleared technologies in medtech and clean energy. At Izotropic, he manages engineering, manufacturing, clinical deployment, and operational scale-up.

Izotropic Corp. (OTCQB: IZOZF), closed Friday's trading session at $0.25475, even for the day, on 1,000 volume. The average volume for the last 3 months is 24,440 and the stock's 52-week low/high is $0.0186/$0.3316.

Recent News

• Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) - InvestorNewsBreaks - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection
• Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging
• Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Questions are mounting in Silicon Valley over whether the skyrocketing valuations of artificial intelligence firms are truly justified. A growing number of investors and analysts are warning that the sector may be inflating faster than its true potential, raising concerns about a potential financial bubble. OpenAI's CEO Sam Altman has acknowledged that mistakes are inevitable in the current AI investment rush, admitting that some startups will receive "silly amounts" of money. Still, he insists OpenAI's growth reflects real progress, not hype. Kaplan, however, believes warning signs are flashing. He points to companies making ambitious announcements without the money to back them and a rush of retail investors chasing AI stocks. He also worries about the long-term environmental impact of the vast data centers being built to support AI growth. Even if a bubble does form, some in the tech community see a silver lining. Jeff Boudier from Hugging Face noted that the internet itself rose from the excesses of the telecom boom. "Overinvestment brings risks," he said, "but it also lays the groundwork for innovation we can't yet imagine." The question now is whether the flow of investment can keep up with Silicon Valley's soaring ambitions—or if Nvidia's billions represent the last major bet before the market cools. What is certain is that some tech companies like D-Wave Quantum Inc. (NYSE: QBTS) are advancing novel technologies whose full impact will gradually unfold as uptake increases. What is now seen as a bubble in the making could eventually turn out to a seismic shift in the investment landscape. 

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave") a leader in quantum computing systems, software, and services, announced an agreement with Swiss Quantum Technology SA ("SQT") to deploy a D-Wave Advantage2 ^TM annealing quantum computer in Europe. The agreement represents a €10M multi-year QCaaS commitment from SQT, with an option to purchase the system. Placement of the SQT funded Advantage2 system supports Italy's newly formed Q-Alliance, an initiative focused on establishing Italy's quantum leadership. Capable of solving complex computational problems beyond the reach of classical computers, the Advantage2 system funded by SQT will be accessible to customers via D-Wave's Leap real-time quantum cloud service. Featuring D-Wave's most advanced quantum processor to date, the 4,400+ qubit Advantage2 system is a powerful and energy-efficient quantum computer designed to facilitate quantum and hybrid quantum applications for production deployment. "The agreement with SQT is an important milestone in our ongoing effort to expand global access to our fleet of annealing quantum computers and to help our rapidly growing customer base solve computationally complex problems faster and more efficiently," said Dr. Alan Baratz, CEO of D-Wave. "As Europe extends its quantum leadership, we believe that D-Wave's production-grade annealing quantum computing technology will serve as a critical component, fueling quantum application development and adoption now."

To view the full press release, visit https://ibn.fm/h9GAC

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $38.33, off by 5.2645%, on 45,679,743 volume. The average volume for the last 3 months is 70,372,975 and the stock's 52-week low/high is $0.975/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Concerns Grow in Silicon Valley About Possible AI Bubble
• EU Speeds Up AI Plans, Injects $578M in Six More?AI Factories
• BillionDollarBreaks - D-Wave Quantum Inc. (NYSE: QBTS) Named Winner in Fast Company's 2025 Next Big Things in Tech Awards

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB).

The company continues to expand its role in the global electronic monitoring ("EM") market, securing new contracts in the U.S. and Europe.

PureSecurity(TM) platform integrates GPS, RFID, and mobile-based monitoring solutions for a range of public safety programs.

EM technology for offender monitoring has demonstrated significant reductions in recidivism across international studies, underscoring its growing importance in justice reform.

SuperCom's recent win in Virginia marks its second engagement in the state since May 2025, reflecting accelerated U.S. growth.

In Germany, SuperCom secured a national contract worth approximately $7 million, replacing a long-standing provider of over two decades.

The company has signed more than 30 new contracts globally since mid-2024, expanding its footprint in offender tracking and domestic violence prevention.

SuperCom (NASDAQ: SPCB) , a global provider of secured e-Government, IoT, and cybersecurity solutions, is cementing its position as a key player in the growing market for electronic monitoring ("EM"). With new contract wins across North America and Europe, the company is seeing strong adoption of its modular PureSecurity(TM) platform, which integrates GPS, RFID, and cloud-based tracking systems into one unified solution.

SuperCom Ltd. (NASDAQ: SPCB) is a global provider of secure solutions spanning electronic monitoring, e-Government, and cybersecurity markets. Since 1988, the company has supported national governments and public agencies with advanced safety, identity, and tracking technologies. Its solutions enable courts, service providers, and public safety agencies to efficiently supervise high-risk populations, improve victims’ safety and manage compliance with judicial mandates across multiple jurisdictions.

SuperCom’s growth in North America has accelerated since mid-2024, with expansion into 11 new U.S. states and more than 30 contracts secured with public safety agencies and regional service providers, displacing long-standing incumbents in the process. This expansion reflects the company’s emphasis on recurring revenue, technological differentiation, and close partnership with agencies seeking innovative, mobile-first alternatives to outdated systems.

SuperCom’s vision is to revolutionize the public safety sector through proprietary electronic monitoring technology, data intelligence, and flawless execution. Its offerings include GPS and RF-based monitoring, biometric ID verification, mobile law enforcement tools, and national-level e-ID platforms.

The company is headquartered in Tel Aviv, Israel.

Products

Electronic Monitoring and Public Safety

SuperCom’s operations are anchored by its proprietary PureSecurity™ suite, a unified offender monitoring platform combining GPS tracking, biometric verification, tamper detection, and advanced data analytics. Its PureOne™ one-piece bracelet and PureTrack™ smartphone-integrated solution offer high-precision location tracking, real-time alerts, and seamless integration with PureCom™ base stations, PureBeacon™ indoor trackers, and PureProtect™, an app designed to safeguard domestic violence victims.

The company complements its hardware with PureMonitor™, a secure, cloud-based case management system that enables real-time oversight, mobile access, and data visualization for monitoring agencies. This full-stack approach allows SuperCom to support a range of court-mandated programs including GPS monitoring, house arrest, curfew enforcement, and community supervision. The company’s domestic violence monitoring solutions are now deployed in at least seven countries.

SuperCom’s U.S. subsidiary, Leaders in Community Alternatives (LCA), provides reentry and rehabilitation services that complement the company’s electronic monitoring programs. Operating primarily in California, LCA delivers community-based solutions designed to reduce recidivism and promote successful reintegration. Its programs include individualized case management, employment support, evidence-based treatment, and day reporting centers—services that support public safety while offering alternatives to incarceration. Since LCA’s acquisition in 2016, SuperCom secured over $35 million in new contract wins in Northern California.

Cybersecurity

SuperCom also offers additional capabilities through its cybersecurity and e-Government product lines. The company’s cybersecurity subsidiary, Safend Ltd., provides endpoint data protection through its Data Protection Suite. This platform includes modules for encryption (Encryptor), port/device control (Protector), data classification (Discoverer), DLP (Inspector), audit tracking (Auditor), and compliance reporting (Reporter).

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments and national agencies design and issue secured multi-identification documents and robust digital identity solutions to their citizens, visitors, and lands. The company has focused on expanding its activities, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

SuperCom operates across multiple high-growth sectors. In electronic monitoring, rising incarceration costs, overcrowded prisons, and increased judicial adoption of alternatives to detention continue to drive demand for GPS and RF-based supervision programs. The company’s rapid expansion into 11 U.S. states and multiple national-level deployments in Europe and the EMEA region reflect a robust and growing market. According to Mordor Intelligence, the electronic offender monitoring solutions market size stands at $2.18 billion in 2025 and is projected to reach $3.19 billion by 2030.

SuperCom also addresses two important supplementary markets through its cybersecurity and e-Government offerings. In cybersecurity, growing threats to sensitive government and enterprise data are fueling investments in endpoint protection, compliance, and device control, which are areas directly served by the company’s Safend platform. In the public sector identity space, secure ID, biometric verification, and e-passport programs remain foundational to digital governance. SuperCom’s track record of delivering national ID solutions across Africa, Latin America, and Eastern Europe underscores its continued relevance in these adjacent sectors.

Leadership Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

SuperCom Ltd. (NASDAQ: SPCB), closed Friday's trading session at $10.24, off by 3.2136%, on 75,536 volume. The average volume for the last 3 months is 112,498 and the stock's 52-week low/high is $3.03/$18.95.

Recent News

• SuperCom Ltd. (NASDAQ: SPCB) - SuperCom Ltd. (NASDAQ: SPCB) Cements Leading Role in Electronic Monitoring with New Contracts, Technological Advancements
• TechMediaBreaks - SuperCom Ltd. (NASDAQ: SPCB) Secures Second Electronic Monitoring Contract in Utah
• SuperCom Ltd. (NASDAQ: SPCB) Expands U.S. Footprint with Second Virginia Contract, 12th New Reseller Agreement Since Mid-2024

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Brain tumors, such as glioblastoma, are very hard to treat and even surgery isn't sufficient to fully remove the tumor since tiny particles of cancerous cells remain and proliferate within a short time. However, ongoing work at Cedars-Sinai promises to transform brain cancer treatment by creating a digital twin of a patient's tumor and then predicting how the cancer will grow and how it could respond to different therapies. In this way, treatment teams can better personalize treatments for individual patients. At the heart of this work is Kristin Swanson, PhD, who is engaged in pioneering work that combines mathematics and neuro-oncology. The goal of this multi-disciplinary team is to make it possible to develop predictive models for disease-processes that currently seem unpredictable. At the moment, the team has been successful in conducting preliminary studies on their approach and they are now working to have their system approved by the FDA for use in selecting participants for different clinical trials testing brain cancer therapies. Thereafter, they hope to advance their system to the level where it can be approved for use in hospital settings so that brain tumor specialists can use it in treating patients. As this system makes its way towards integration in patient care, brain cancer therapies like those being developed by companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) could have a better impact if they are selected for the patients who are most likely to benefit from them. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $9.2, off by 3.0558%, on 12,368 volume. The average volume for the last 3 months is 47,943 and the stock's 52-week low/high is $4.93/$221.94.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Virtual Brain Tumors Could Transform How Cancer is Treated
• New AI Tool Boosts Precision Medicine in Treating CNS Cancers
• Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)

The QualityStocks Daily Newsletter would like to spotlight Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ).

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) is emerging as a key player at the intersection of national security and critical mineral supply amid growing U.S. urgency to reduce dependence on China for essential resources. Its 50%-owned Upper Kobuk Mineral Projects in Alaska—rich in copper, zinc, cobalt, and lead—align with a broader federal pivot toward supporting domestic mining, highlighted by a historic visit from the U.S. House Committee on Natural Resources and increasing Pentagon interest in securing strategic materials. With robust reserves, a $1.5 billion project valuation, and strong state and federal backing, Trilogy is positioned to benefit from market demand and shifting U.S. policy, especially as the proposed Ambler Access Road gains recognition as vital infrastructure for mineral security.

To view the full article, visit https://ibn.fm/dkZI6

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) is a North American mineral exploration and development company focused on advancing high-grade copper and critical mineral assets in Alaska. The company operates through Ambler Metals LLC, a 50/50 joint venture with South32 Ltd., and is progressing one of the world’s most prospective undeveloped polymetallic districts.

Trilogy is uniquely positioned with exposure to copper, zinc, lead, cobalt, silver, and gold—commodities vital to global electrification and energy transition. Its vision is to responsibly develop the Ambler Mining District into a premier domestic source of critical minerals while delivering long-term value to shareholders and local communities.

The company is guided by values of trust, respect, integrity, and partnership, and works closely with Alaska Native stakeholders to advance its strategy in a sustainable and inclusive manner.

Projects

Arctic Project

The Arctic project is Trilogy’s flagship asset and one of the highest-grade known copper deposits in the world, with an average grade of approximately 5% copper equivalent. Located roughly 470 kilometers northwest of Fairbanks, Alaska, Arctic is a volcanogenic massive sulphide (VMS) deposit hosting copper, zinc, lead, gold, and silver. The project is at the feasibility stage and is currently undergoing permitting activities.

According to the 2023 Feasibility Study, Arctic will support a 10,000 tonne-per-day open-pit mining operation over a 13-year mine life. Based on long-term metal prices of $3.65/lb copper, $1.15/lb zinc, $1.00/lb lead, $1,650/oz gold, and $21.00/oz silver, the project demonstrates a pre-tax NPV8% of $1.5 billion and an IRR of 25.8%. After-tax, the NPV8% is $1.1 billion with a 22.8% IRR. At April 2025 spot metal prices, the after-tax NPV8% increases to $1.9 billion with a 31.1% IRR.

The project’s metallurgy supports high recoveries: 92.1% for copper, 88.5% for zinc, and 61.3% for lead. Life-of-mine payable production is projected to total 1.9 billion pounds of copper, 2.2 billion pounds of zinc, 335 million pounds of lead, 423,000 ounces of gold, and 36 million ounces of silver. Cash costs are expected to average $0.72 per pound of payable copper, with all-in costs estimated at $1.61 per pound.

Bornite Project

Located approximately 25 kilometers southwest of Arctic, the Bornite project is a large-scale carbonate replacement copper deposit with significant upside. According to the 2025 Preliminary Economic Assessment (PEA), Bornite is expected to support a 6,000 tonne-per-day underground operation over a 17-year mine life, using re-purposed infrastructure from the Arctic Project.

Bornite contains an estimated 6.5 billion pounds of inferred copper. The PEA outlines pre-tax NPV8% of $552.1 million and IRR of 23.6%, with an after-tax NPV8% of $393.9 million and IRR of 20.0%, based on a copper price of $4.20/lb. Total payable copper production over the life of mine is projected at 1.9 billion pounds.

Bornite’s mineralization occurs in stacked, stratabound zones rich in chalcopyrite, bornite, and chalcocite. A subset of the South Reef zone offers high-grade underground mining potential, further enhancing Bornite’s future optionality.

Exploration Pipeline

The Upper Kobuk Mineral Projects span 471,796 acres and include more than 30 additional mineralized prospects beyond Arctic and Bornite. These lie along two geologically distinct and highly mineralized belts: the Ambler Schist Belt and the Bornite Carbonate Sequence.

The Ambler Schist Belt features multiple VMS-style prospects along its 100-kilometer strike length, including Sunshine, Snow, Nora, Shungnak, and BT. Neighboring deposits like Smucker (Teck) and Sun (Valhalla Metals) affirm the district’s regional potential. Ten of Trilogy’s VMS prospects have been drill tested with encouraging results.

Meanwhile, the Bornite Carbonate Sequence extends 16 kilometers along the Cosmos Hills and hosts additional targets such as Pardner Hill and Aurora Mountain. These zones show strong signs of copper and cobalt mineralization and were partially tested during the Kennecott era, suggesting significant room for expansion.

Together, these assets form the foundation of a multi-decade development and discovery platform in one of the most prospective undeveloped mining districts in North America.

Market Opportunity

Trilogy Metals is poised to benefit from long-term structural demand for copper and other critical minerals essential to electrification, energy infrastructure, and clean technologies. Copper, in particular, is expected to see major supply shortfalls due to underinvestment and accelerating demand from power grids, EVs, and data centers.

According to a Grand View Research report, the global copper market is projected to grow from $241.88 billion in 2024 to $339.95 billion by 2030, at a CAGR of 6.5%, driven by the energy transition and rising infrastructure investments.

Trilogy’s Arctic and Bornite projects are strategically located in Alaska, a top-tier mining jurisdiction with strong permitting frameworks and growing federal and state-level support, including recent executive orders streamlining approvals for the Ambler Access Project. The company also maintains a $50 million shelf prospectus and an active $25 million ATM equity program to fund future development.

Leadership Team

Tony Giardini, President and Chief Executive Officer, leads Trilogy Metals with extensive executive experience in the mining industry. He previously served as President of Ivanhoe Mines Ltd., and as Executive Vice President and Chief Financial Officer at Kinross Gold Corporation. Earlier in his career, he held senior roles at Placer Dome Inc. and KPMG. Mr. Giardini is both a Chartered Professional Accountant and a Certified Public Accountant.

Elaine M. Sanders, Chief Financial Officer and Corporate Secretary, brings over 25 years of financial and accounting experience to Trilogy. She is responsible for the company’s financial reporting, compliance, and governance functions. Ms. Sanders has overseen multiple financings and exchange listings throughout her career. She holds a Bachelor of Commerce from the University of Alberta and is both a Chartered Professional Accountant and Certified Public Accountant.

Richard Gosse, Vice President, Exploration, is a veteran geologist with 35 years of global exploration experience. He previously led exploration initiatives at Dundee Precious Metals and Ivanhoe Mines Ltd., where he oversaw the discovery efforts at the renowned Oyu Tolgoi copper-gold project in Mongolia. Mr. Gosse holds a B.Sc. in Geology from Queen’s University and an M.Sc. in Mineral Exploration from Imperial College London.

Trilogy Metals Inc. (NYSE American: TMQ), closed Friday's trading session at $6.46, off by 9.0141%, on 15,852,875 volume. The average volume for the last 3 months is 25,666,937 and the stock's 52-week low/high is $0.551/$11.29.

Recent News

• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) - MiningNewsBreaks - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Poised for Dual Value Creation from Market Demand, Domestic Policy
• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Positioned for Growth as AI Data Centers Drive Copper Demand
• MiningNewsBreaks - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Stock Surges on Reported 10% Trump Administration Stake and EO for Ambler Road Permits

West Vault Mining Inc. (TSX.V: WVM) (OTCQX: WVMDF)

The QualityStocks Daily Newsletter would like to spotlight West Vault Mining Inc. (TSX.V: WVM) (OTCQX: WVMDF).

West Vault Mining Inc. (West Vault) has a long-term bullish outlook for gold

West Vault seeks lower risk and higher long-term returns by keeping its gold in the ground

West Vault has substantially derisked its Hasbrouck Gold Project located in mining-friendly Nevada through completion of a PFS and obtaining all major permits

A Safe Haven Reasserts Itself

Gold's reputation as a hedge against inflation, weakening currencies and market volatility has rarely felt more relevant. Global investors, from central banks to individuals, continue accumulating the metal as protection against persistent inflation, geopolitical conflict, and the uncertain trajectory of monetary policy.  Many analysts are forecasting rising gold prices, driven by geopolitical tensions and recessionary tailwinds.  With gold already trading over US$4,200 per oz, such forecasts are trending higher. On October 15th J.P. Morgan Chase Chief Executive Officer Jamie Dimon stated that gold "could easily go to $5,000 or $10,000 in environments like this". With such forecasts as a backdrop, advanced-stage projects in safe jurisdictions are attracting greater attention as future sources of supply.

West Vault's Strategy

West Vault Mining (TSX.V: WVM) (OTCQX: WVMDF) is a different kind of gold company. It is value driven, seeking to do things that are accretive to long term value per share while not exposing shareholders to development and financing risk until the risk-reward balance is compelling.  What is often missed by investors is that the per ounce cost of holding gold reserves in the ground is typically lower than holding the same number of ounces in a bank vault.  West Vault seeks to provide investors with a platform to hold gold in the ground, and the opportunity to achieve low risk, high long-term returns by minimizing permitting risk, construction risk, operating risk, financial risk, and geopolitical risk.  Reducing risks can lower the assumed discount rate to net asset value ("NAV") while maximizing long-term exposure to gold. How does West Vault provide exposure to gold in the ground and lower risks?  Its 100% owned Hasbrouck Gold Project in Nevada has secured all major development permits and is construction-ready, resulting in low permitting risk.  Until a decision is taken to construct and operate a mine, or sell the project, exposure to construction and operating risk does not occur.  Likewise, West Vault seeks to reduce the risk and dilution to shareholders associated with mine financing by waiting for the most opportune economic circumstances – when higher gold prices provide exceptional returns at a low cost of capital.  With the project located in Nevada, amongst the safest, most mining-friendly jurisdictions globally, geopolitical risk is substantially reduced.

West Vault Mining Inc. (TSX.V: WVM) (OTCQX: WVMDF) is a development-stage gold company focused on maximizing shareholder value through a low-risk, cash-conservative strategy. The company has followed a disciplined model of acquiring, advancing, and holding high-quality gold projects in premier jurisdictions, with the goal of monetizing these assets as market conditions become favorable. Its core emphasis is on controlling dilution and timing development decisions to optimize shareholder returns across the commodity cycle.

Since its formation following the successful C$424 million sale of West Timmins Mining in 2009, West Vault has remained laser-focused on opportunities in North America’s most prolific gold-bearing regions. This strategy has led to the acquisition and advancement of its flagship Hasbrouck Gold Project in Nevada, which is permitted and construction ready.

With a highly experienced management team and board that emphasize transparency, capital discipline, and long-term alignment with shareholders, West Vault is positioned as a unique vehicle offering exposure to gold price upside without the risks associated with early-stage construction.

The company is headquartered in Vancouver, British Columbia.

Project

West Vault controls a 100% interest in the Hasbrouck Gold Project, located between Tonopah and Goldfield in Nevada’s prolific Walker Lane Trend. The project comprises two primary oxide gold deposits—Three Hills and Hasbrouck—spanning a 10,500-acre land package. Both deposits are situated above the water table, with excellent infrastructure access including nearby grid power, highway connections, and water rights.

The company’s strategy is grounded in maintaining shovel-ready optionality. The most recent Pre-feasibility Study “base case”, completed in January 2023 by RESPEC Company LLC, reaffirmed the strength of the Hasbrouck Project, demonstrating an after-tax Net Present Value (NPV5%) of US$206 million and an Internal Rate of Return (IRR) of 51% at a gold price of $1,790/oz—well below current prices. In the Pre-feasibility Study sensitivity table, a $2,600/oz gold price resulted in an after-tax Net Present Value (NPV5%) of US$503 million and an Internal Rate of Return (IRR) of 110%. Phase 1 (Three Hills Mine) is expected to require a modest initial capital investment of US$66 million in 2023 dollars, with the Phase 2 (Hasbrouck Mine) development planned to be funded through free cash flow from Three Hills. Average gold production is projected at 71,000 ounces per year with an all-in sustaining cost (AISC) of US$877 per ounce.

The project benefits from a low strip ratio (1.1:1), no pre-stripping requirements at the first pit, and a simple run-of-mine heap leach process with a 75% average gold recovery based on 13 metallurgical test programs. In addition to its existing Mineral Reserves and Resources, West Vault retains strong exploration upside, including intercepts outside the current resource model and a 1% NSR royalty on properties adjacent to Hasbrouck, enhancing long-term value potential.

Market Opportunity

West Vault’s cash-conservative approach and construction-ready asset position the company to capitalize on favorable shifts in the gold market without taking on near-term development or financing risk.

According to J.P. Morgan Research, gold prices are forecast to average $3,675 per ounce by the fourth quarter of 2025 and trend toward $4,000 per ounce by mid-2026, driven by persistent geopolitical tensions, demand rebasing, and recessionary tailwinds. With its permitted status, minimal overhead, and leverage to gold price appreciation, West Vault is strategically positioned to benefit from these macroeconomic tailwinds.

Leadership Team

Peter Palmedo, Chairman and Director, is the founder and president of Sun Valley Gold LLC, where he has spent more than 25 years investing in precious metals as a strategic asset class. Prior to founding SVG, he was a principal at Morgan Stanley & Co., specializing in equity portfolio risk management and derivatives. He served as a director of Chesapeake Gold Corp. until 2013 and joined the board of West Vault in 2019.

Sandy McVey, Chief Executive Officer and Chief Operating Officer, is a Professional Mining Engineer and registered Project Management Professional with over 30 years of experience in underground and surface mine operations, heavy civil construction, and mine development. He joined West Vault Mining in 2012 to lead the advancement, permitting, and construction of the company’s projects and has been instrumental in acquiring and bringing the Hasbrouck Gold Project to a construction-ready state.

Frank Hallam, Chief Financial Officer and Corporate Secretary, is a Chartered Professional Accountant with more than 30 years of experience in the mining, minerals, and petroleum industries. He has served as an operator, principal, and founder of several TSX and NYSE American companies, including Platinum Group Metals, MAG Silver, and West Timmins Mining. He has raised over $2 billion in public offerings and been directly involved in numerous M&A transactions, including the C$424 million sale of West Timmins and the billion-dollar acquisition of Lake Shore Gold by Tahoe Resources.

West Vault Mining Inc. (OTCQX: WVMDF), closed Friday's trading session at $1.48, off by 5.1282%, on 12,859 volume. The average volume for the last 3 months is 24,170 and the stock's 52-week low/high is $0.6/$1.6599.

Recent News

• West Vault Mining Inc. (TSX.V: WVM) (OTCQX: WVMDF) - West Vault Mining Inc. (TSX.V: WVM) (OTCQX: WVMDF): Gold Exposure by Holding Nevada Gold Reserves in the Ground
• InvestorNewsBreaks - West Vault Mining Inc. (TSXV: WVM) (OTCQX: WVMDF) CEO Featured on Latest Episode of The MiningNewsWire Podcast
• MissionIRNewsBreaks - Why West Vault Mining Inc. (TSX.V: WVM) (OTCQX: WVMDF) Is 'One to Watch'

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) , doing business as TechForce Robotics, announced it is generating approximately $10 million in annualized revenue through its portfolio of income-producing robotics and hospitality assets. The milestone underscores the company's transition into a high-growth enterprise built on hotel acquisitions and its expanding Robotics-as-a-Service (RaaS) platform. CEO Jimmy Chan said the achievement validates NGTF's integrated growth model and highlights the company's focus on scaling its AI-driven hospitality automation strategy to deliver long-term shareholder value.

To view the full press release, visit https://ibn.fm/yinLn

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Friday's trading session at $0.0492, off by 1.6%, on 683,831 volume. The average volume for the last 3 months is 716,380 and the stock's 52-week low/high is $0.0053/$0.069.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Achieves $10 Million in Annualized Revenue Through AI-Driven Hospitality Expansion
• TechMediaBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Expands TechForce Robotics Live Pilots Across Multiple High-Traffic Industries
• TechMediaBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Completes $52.8 Million Acquisition of Hilton Garden Inn Rancho Mirage as Part of TechForce Robotics Expansion

AI Maverick Intel Inc. (OTC: BINP)

The QualityStocks Daily Newsletter would like to spotlight AI Maverick Intel Inc. (OTC: BINP).

AI Maverick Intel Inc. (OTC: BINP) is a technology-forward company focused on transforming how businesses acquire and engage customers through artificial intelligence. With a growth strategy centered on acquiring revenue-generating businesses, the company leverages its proprietary platform to deliver scalable, automated solutions across key sectors including healthcare, biotech, insurance, and transportation.

The company’s vision is to eliminate friction from the customer acquisition process by replacing traditional, resource-heavy outreach with intelligent, automated engagement. Its mission is to empower organizations to connect with their ideal audiences at high velocity, using real-time insights and personalized communication powered by machine learning.

AI Maverick Intel is committed to creating long-term value through innovation, efficiency, and strategic partnerships that enhance operational performance and accelerate growth.

The company is headquartered in Dallas, Texas.

Platform & Operations

AI Maverick’s proprietary technology powers a fully automated, AI-driven prospecting engine that enables businesses to scale customer acquisition without expanding headcount. In July 2025, the company launched its enhanced platform, capable of managing both transactional and consultative sales engagements with human-like fluency.

Key components include:

• Comprehensive Contact Intelligence – Aggregates millions of structured and unstructured data points to build dynamic profiles highlighting job changes, buying intent, and preferences.
• Context-Aware Messaging – Adaptive language models tailor tone, timing, and delivery channel for each interaction to maximize engagement.
• Autonomous Sales Dialogues – Manages discovery questions, handles objections, and schedules follow-ups, traditionally handled by sales reps.

This solution supports two-way communication across the full sales funnel—from quote generation and renewals to needs analysis and solution recommendations. The platform is designed to accelerate deal flow and reduce acquisition costs, with typical deployments completed in under a day.

AI Maverick’s transition into an AI-first company followed its acquisition of the AI Maverick platform in May 2025 and a formal rebrand later that month. The company’s public identity now aligns with its operational direction, targeting continued growth through platform scale and strategic business combinations.

Market Opportunity

AI Maverick Intel operates within the rapidly growing artificial intelligence in marketing sector, where machine learning is being widely adopted to personalize customer engagement, optimize ad performance, and automate sales interactions. According to Grand View Research, the global AI in marketing market was valued at $20.44 billion in 2024 and is projected to reach $82.23 billion by 2030, representing a compound annual growth rate (CAGR) of 25.0% from 2025 to 2030.

This growth is being driven by increased demand for individualized consumer experiences, expanded adoption of social networking platforms, and the continued rise of online shopping. North America currently leads the market with a 32.4% revenue share, while Asia Pacific is expected to see the fastest growth. Key applications include content curation, dynamic ad creation, and real-time audience targeting, which are consistent with the platform’s intended use cases.

As companies across industries prioritize speed, accuracy, and scale in reaching their target audiences, AI Maverick’s automation-first approach positions it to capitalize on a multi-billion-dollar transformation in how modern customer acquisition is executed.

Leadership Team

Wayne Cockburn, Chief Executive Officer, is an experienced business executive with over 25 years of board experience across public and private companies in both the U.S. and Canada. He has held senior leadership roles in healthcare and financial services firms, with past titles including Executive Vice President at MedX Health Corp., Chairman of Niiomed Inc., and President of Pathway Health Corp. He is skilled in M&A, capital markets, governance, and startup development, and holds a bachelor’s degree from York University’s Glendon College.

AI Maverick Intel Inc. (OTC: BINP), closed Friday's trading session at $0.038, up 26.6667%, on 2,500 volume. The average volume for the last 3 months is 14,320 and the stock's 52-week low/high is $0.0162/$0.448.

Recent News

• AI Maverick Intel Inc. (OTC: BINP) - AI Maverick Intel Inc. (BINP) Poised to Help Businesses Optimize the Customer Acquisition Experience Using AI
• AINewsBreaks - AI Maverick Intel Inc. (BINP) Moves Beyond Lead Gen with Consultative Sales Platform
• AI Maverick Intel Inc. (BINP) Transforms Customer Acquisition with AI-Driven Automation

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Friday's trading session at $1.65, up 6.4516%, on 485,286 volume. The average volume for the last 3 months is 2,388,655 and the stock's 52-week low/high is $1.09/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
• Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
• Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Friday's trading session at $3.18, up 4.6053%, on 1,195,402 volume. The average volume for the last 3 months is 443,085 and the stock's 52-week low/high is $1.12/$6.01.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies
• MissionIRNewsBreaks - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs
• BioMedNewsBreaks - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies